Effects of smoking on the association of HLA with ulcerative colitis.

Effects of smoking on the association of HLA with ulcerative colitis. J Gastroenterol Hepatol. 2019 Apr 30;: Authors: Lee HS, Kim K, Jung S, Hong M, Kim BM, Yoo DS, Moon JW, Baek J, Hwang SW, Park SH, Yang SK, Han B, Song K, Ye BD Abstract BACKGROUND AND AIM: Tobacco smoking is a risk factor for gastrointestinal disorders, causing mucosal damage and impairing immune responses. However, smoking has been found to be protective against ulcerative colitis (UC). Human leukocyte antigen (HLA) is a major susceptibility locus for UC, and…

Read More

Association of TRAP1 with Infliximab-Induced Mucosal Healing in Crohn’s disease.

Association of TRAP1 with Infliximab-Induced Mucosal Healing in Crohn’s disease. J Gastroenterol Hepatol. 2019 Apr 30;: Authors: Park SH, Hong M, Lee HS, Ye BD, Hwang SW, Jung S, Baek J, Moon J, Kim BM, Oh SH, Kim KM, Lee I, Im CN, Liu J, McGovern DPB, Yang SK, Song K Abstract BACKGROUND AND AIM: Anti-tumour necrosis factor (TNF) agents, such as infliximab (IFX), have been increasingly used to induce and maintain disease remission in patients with Crohn’s disease (CD). Despite a considerable non-response rate, little is known about the…

Read More

Remission Induction, Maintenance, and Endoscopic Outcome with Oral 5-Aminosalicylic Acid in Intestinal Behçet’s Disease.

Remission Induction, Maintenance, and Endoscopic Outcome with Oral 5-Aminosalicylic Acid in Intestinal Behçet’s Disease. J Gastroenterol Hepatol. 2019 Apr 24;: Authors: Kinoshita H, Nishioka H, Ikeda A, Ikoma K, Sameshima Y, Ohi H, Tatsuno M, Kouyama J, Kawamoto C, Mitsui T, Tamura Y, Hashimoto Y, Nishio M, Ogashiwa T, Saigusa Y, Maeda S, Kimura H, Kunisaki R, Koike K Abstract BACKGROUND AND AIM: Oral 5-aminosalicylic acid (5-ASA) is recommended for the therapy of mild to moderate intestinal Behçet’s disease (BD). However, the induction remission efficacy and endoscopic outcomes of 5-ASA…

Read More

The usefulness of intestinal real-time virtual sonography in patients with inflammatory bowel disease.

The usefulness of intestinal real-time virtual sonography in patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2019 Apr 01;: Authors: Kawai S, Iijima H, Shinzaki S, Hiyama S, Yamaguchi T, Araki M, Iwatani S, Shiraishi E, Mukai A, Inoue T, Tsujii Y, Hayashi Y, Tsujii M, Takehara T Abstract BACKGROUND AND AIM: Trans-abdominal ultrasonography (US) examination for the intestine is often difficult and its precedence for intestinal examination depends on accessibility to experienced ultrasonographers. Real-time virtual sonography (RVS) assists examination of US as a fusion method by synchronizing US images…

Read More

Epidemiology, characteristics and survival of post-colonoscopy colorectal cancer in Asia: a population-based study.

Epidemiology, characteristics and survival of post-colonoscopy colorectal cancer in Asia: a population-based study. J Gastroenterol Hepatol. 2019 Apr 01;: Authors: Cheung KS, Chen L, Seto WK, Leung WK Abstract BACKGROUND AND AIMS: Population-based studies on post-colonoscopy colorectal cancer (CRC) from Asia are sparse. We aimed to determine the characteristics and predictive factors and survival of post-colonoscopy CRC in Hong Kong. METHODS: This is a territory-wide retrospective cohort study. Patients aged ≥40 years with colonoscopies performed between 2005 and 2013 without history of CRCs, inflammatory bowel disease and prior colectomy were…

Read More

ZNF133 Is Associated with Infliximab Responsiveness in Patients with Inflammatory Bowel Diseases.

ZNF133 Is Associated with Infliximab Responsiveness in Patients with Inflammatory Bowel Diseases. J Gastroenterol Hepatol. 2019 Mar 09;: Authors: Jung ES, Choi KW, Kim SW, Hübenthal M, Mucha S, Park J, Park Z, Ellinghaus D, Schreiber S, Franke A, Oh WY, Cheon JH Abstract BACKGROUND AND AIM: Infliximab has been widely prescribed for treating inflammatory bowel disease (IBD). However, the response rates to infliximab differ among patients. Therefore, we aimed to identify the genetic and clinical markers that predict infliximab response. METHODS: A total of 139 Korean patients with IBD…

Read More

Best practices on immunomodulators and biological agents for Ulcerative colitis and Crohn’s disease in Asia.

Best practices on immunomodulators and biological agents for Ulcerative colitis and Crohn’s disease in Asia. J Gastroenterol Hepatol. 2019 Mar 08;: Authors: Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Raja Ali RA, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RWL,…

Read More

Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study.

Related Articles Long-term efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J Gastroenterol Hepatol. 2019 Mar 03;: Authors: Kim NH, Lee JH, Hong SN, Yoon H, Kang HW, Lee SH, Im JP, Cha JM, Eun CS, Kim JW, Choi CH, Park DI Abstract BACKGROUND AND AIM: A biosimilar of infliximab, CT-P13 (Remsima®) has the potential to reduce treatment costs and enhance access to biological therapy for inflammatory bowel disease (IBD) patients. However, long-term clinical data on its use for…

Read More

Association between dietary iron and zinc intake and development of ulcerative colitis: A case-control study in Japan.

Association between dietary iron and zinc intake and development of ulcerative colitis: A case-control study in Japan. J Gastroenterol Hepatol. 2019 Mar 01;: Authors: Kobayashi Y, Ohfuji S, Kondo K, Fukushima W, Sasaki S, Kamata N, Yamagami H, Fujiwara Y, Suzuki Y, Hirota Y, Japanese Case-Control Study Group for Ulcerative Colitis Abstract BACKGROUND AND AIM: The prevalence of ulcerative colitis (UC) has been increasing in Japan. Trace elements such as iron, zinc, magnesium and copper, can cause digestive symptoms where there is a deficiency or excess. We focused on the…

Read More

Outcomes of ulcerative colitis-associated dysplasia patients referred for potential endoscopic submucosal dissection.

Outcomes of ulcerative colitis-associated dysplasia patients referred for potential endoscopic submucosal dissection. J Gastroenterol Hepatol. 2019 Feb 06;: Authors: Yang DH, Kim J, Song EM, Chang K, Lee SH, Hwang SW, Park SH, Ye BD, Byeon JS, Myung SJ, Yang SK Abstract BACKGROUND: The feasibility of endoscopic submucosal dissection (ESD) as a treatment option for dysplasia in ulcerative colitis (UC) has been reported but the associated therapeutic decision-making and clinical outcomes have not been extensively investigated. METHODS: We retrospectively reviewed 25 UC patients who were referred for potential ESD of…

Read More
<< Go Back